These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 32641071

  • 1. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T, Adams D, Conceição I, Waddington-Cruz M, Schmidt HH, Buades J, Campistol J, Berk JL, Polydefkis M, Wang JJ, Chen J, Sweetser MT, Gollob J, Suhr OB.
    Orphanet J Rare Dis; 2020 Jul 08; 15(1):179. PubMed ID: 32641071
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, patisiran Global OLE study group.
    Lancet Neurol; 2021 Jan 08; 20(1):49-59. PubMed ID: 33212063
    [Abstract] [Full Text] [Related]

  • 3. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP, Yang CC, Lee YC, Lee MJ, Vest J, Sweetser MT, White MT, Badri P, Hsieh ST, Chao CC.
    J Formos Med Assoc; 2024 Sep 08; 123(9):975-984. PubMed ID: 38548524
    [Abstract] [Full Text] [Related]

  • 4. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S, Aldinc E, Polydefkis M, Adams D, Coelho T, Ueda M, Hale C, Vest J, Nioi P, Patisiran Global OLE Collaborators.
    Amyloid; 2024 Mar 08; 31(1):1-11. PubMed ID: 37469249
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
    J Clin Pharmacol; 2020 Jan 08; 60(1):37-49. PubMed ID: 31322739
    [Abstract] [Full Text] [Related]

  • 7. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.
    JAMA Cardiol; 2019 May 01; 4(5):466-472. PubMed ID: 30878017
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS, Brandão PRP, Faber I, Titze-de-Almeida R.
    Mol Diagn Ther; 2020 Feb 01; 24(1):49-59. PubMed ID: 31701435
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D.
    J Neurol; 2020 Mar 01; 267(3):703-712. PubMed ID: 31728713
    [Abstract] [Full Text] [Related]

  • 13. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB.
    N Engl J Med; 2018 Jul 05; 379(1):11-21. PubMed ID: 29972753
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H.
    Expert Opin Pharmacother; 2021 Jan 05; 22(1):121-129. PubMed ID: 32892660
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I.
    Clin Auton Res; 2019 Sep 05; 29(Suppl 1):11-17. PubMed ID: 31399774
    [Abstract] [Full Text] [Related]

  • 20. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.
    Neurodegener Dis Manag; 2019 Feb 05; 9(1):5-23. PubMed ID: 30480471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.